THE PURINE NUCLEOSIDE adenosine is well established as an autocrine and paracrine hormone in the cardiovascular system (25, 33) . Adenosine promotes compensatory cellular responses to stress and enhances the ability of cells to recover from severe cellular insult (17, 25, 33) . Adenosine is not lipophilic; therefore, the movement of adenosine across the cell membrane occurs via equilibrative nucleoside transporters (ENTs), which facilitate diffusion of adenosine down its concentration gradient. ENTs are highly expressed in the heart and are likely to play an important, but poorly understood, role in adenosinedependent cellular physiology. Adenosine concentrations in the heart fluctuate enormously depending on cellular metabolic demands and activity of enzymes involved in adenosine metabolism (17) (18) (19) . However, the influence of ENTs on adenosine flux across cardiomyocyte cell membranes is unknown. Clinically, adenosine has been used as an antiarrhythmia drug (41) and adenosine analogs are used, or have been proposed for clinical use, to treat various types of cardiovascular disease (e.g., 12, 33, 44) . Moreover, several clinically important cardiovasodilatory and cardioprotectant drugs, such as dipyridamole, inhibit ENTs, and their use is based on the premise that preventing reuptake of adenosine will potentiate adenosine receptor activation.
Adenosine acts via G protein-coupled receptors linked to a multitude of signaling cascades that have been proposed to regulate activity of other membrane proteins such as ion channels and transporters (2, 49) .
We are interested in the role of ENTs in modulating the effects of adenosine in cardiomyocytes and the role of adenosine in regulating transport processes in cardiomyocytes. Recently, we showed that the cardiomyocyte cell line HL-1 (10) is an excellent model in which to dissect adenosine-dependent pathways involved in cardiomyocyte cellular physiology (9) . HL-1 cells are similar to cardiomyocytes in terms of their adenosine and glucose transport characteristics (9) and have been previously used for studies on cardiomyocyte physiology (e.g., 15, 38, 39, 47) . It has been widely reported that adenosine potentiates insulin-stimulated glucose transport (via specific adenosine receptor-activated pathways) in skeletal muscle (e.g., 24, 52, 55) . However, the role of adenosine in regulating insulin-stimulated glucose transport in cardiomyocytes is less clear, with reports (1, 20, 22, 32, 34) both supporting and discounting a role for adenosine in modulating glucose uptake. Therefore, we asked whether inhibition of ENTs, by the nucleoside transport inhibitors dipyridamole, dilazep, or S-(4-nitrobenzyl)-6-thioinosine (NBTI) to increase extracellular adenosine or treatment with adenosine directly, modulates basal or insulin-stimulated glucose transport in HL-1 cardiomyocytes.
from Roche Molecular Biochemicals (Quebec, Canada). Radiolabeled 2-[ 3 H]deoxy-D-glucose was purchased from American Radiolabeled Chemicals (St. Louis, MO). Ex-Cell 320 and Claycomb media were obtained from JRH Biosciences (Lenexa, KS). Secondary (goat antirabbit horseradish peroxidase conjugated) antibodies were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA). Polyclonal rabbit antibodies, specific for GLUT1 and GLUT4 (25, 26) , were the kind gift of Dr. Amira Klip, Hospital for Sick Children (Toronto, Ontario, Canada).
Cell culture. The HL-1 cells represent a cardiac muscle cell line derived from AT-1 mouse atrial cardiomyocyte tumor lineage and which keeps in vitro phenotypic characteristics of the adult cardiomyocyte (10) . HL-1 cells were obtained from Dr. W. Claycomb (Louisiana State University Medical Center, New Orleans, LA) and were grown as previously described (9) . Briefly, cells were grown as a monolayer (37°C, 5% CO 2) in culture flasks, dishes, and plates precoated with 1 g/cm 2 fibronectin-0.02% (wt/vol) gelatin solution. HL-1 cells were maintained in Claycomb medium supplemented with 10% (vol/vol) fetal bovine serum, 4 mM L-glutamine, 100 M norepinephrine, and 1ϫ antibiotic/antimycotic solution. Cells were confirmed to be mycoplasma free on a regular basis.
Glucose transport studies. Glucose (2-deoxy-D-glucose) uptake assay was performed as previously described (57) . Briefly, HL-1 cells were grown in Ex-Cell 320 medium containing parts A and B (9:1) with 10% (vol/vol) fetal bovine serum in 12-or 24-well plates until 80-90% confluent. Cells were then serum starved for 16-18 h. Cells were preincubated (37°C, 15-30 min) with media alone or with insulin (300 nM), adenosine (50 M, 250 M), 2-chloroadenosine (250 M), or the nucleoside transport inhibitors dipyridamole (3-300 M), dilazep (1-100 M), and NBTI (10-500 nM). Cells were then washed twice with glucose-free HEPES-buffered saline solution [which contained (in mM) 140 NaCl, 5 KCl, 2.5 MgSO4, 1 CaCl2, and 20 HEPES, pH 7.4]. Carrier-mediated glucose uptake was determined after incubation (5 min) with 2-[ 3 H]deoxy-D-glucose (10 M, 60 Ci/mmol, and 1 Ci/l) in the above solution (in the presence or absence of inhibitor) at room temperature. Uptake was terminated by rinsing the cells three times with ice-cold saline solution [0.9% (wt/vol) NaCl], followed by cell disruption with 0.05 N NaOH. Protein concentration was measured by the modified Lowry protein assay. Uptake-associated radioactivity was determined by scintillation counting. Nonspecific 2-deoxy-D-glucose uptake was determined in the presence of 10 M cytochalasin B, and this value was subtracted from all measurements performed at least in quadruplicate for each condition. Specific uptake was expressed as picomoles per milligram of protein per minute.
Analysis of GLUT isoforms. Crude lysates of HL-1 or L6 (positive control) cells were prepared to determine which GLUT isoforms were present. HL-1 cells (100-mm dishes, 90-95% confluent) were placed on ice and washed with ice-cold phosphate-buffered saline. Cells were then scraped into 1 to 2 ml of lysis buffer composed of (in mM) 10 Tris⅐HCl, pH 7.5, 1 EDTA, 0.1 NaCl, and 1 Complete protease inhibitor cocktail tablet (10 ml) and homogenized by being passed through a 26-gauge needle. The homogenate was centrifuged (10 min, 1,000 g, 4°C) to remove cell debris and the supernatant was frozen at Ϫ80°C for later analysis by SDS-PAGE and immunoblotting. The protein concentration of the crude lysate was determined by a modified Lowry protein assay. Protein samples were subjected to SDS-PAGE on 7.5% (wt/vol) acrylamide gel and transferred to polyvinylidene difluoride membranes for 2 h at 100 mV. Membranes were incubated (1 h at room temperature) in blocking solution composed of Tris-buffered saline (TBS) containing (in mM) 150 NaCl and 50 Tris⅐HCl, pH 7. Data analysis. Data were analyzed using Student's paired t-test to compare the mean of differences between two conditions, such as control and insulin treated. A value of P Ͻ 0.05 was considered to be significant. Dose-response curves and inhibition constants were generated using nonlinear regression analyses in GraphPad Prism 3.0 for Macintosh.
RESULTS
GLUT isoforms in HL-1 cells. Whereas basal and insulinstimulated glucose uptake has been previously demonstrated in HL-1 cells (9), the identities of the GLUT isoforms in this cell type have not been determined. GLUT1 and GLUT4 have been shown to be responsible for both basal and insulin-stimulated glucose uptake in rodent cardiomyocytes (3) . SDS-PAGE of HL-1 cell lysates and immunoblotting using well-characterized antibodies (31, 48) and control L6 cell lysates demonstrated that both GLUT1 and GLUT4 isoforms are present in HL-1 cells (Fig. 1) . GLUT4 protein is characterized as a relatively diffuse band of ϳ46-48 kDa. Both proteins were identified by comparison with the known locations of these isoforms in L6 cell lysates (48) .
Inhibition of glucose uptake by dipyridamole and dilazep but not NBTI. Dipyridamole and dilazep have been widely used to promote adenosine-dependent processes in the cardiovascular system based on their inhibition of reuptake of endogenous extracellular adenosine by ENTs and potentiation of adenosine receptor activation (21, 23, 35, 53, 54) . Dilazep and dipyridamole (at micromolar concentrations) will effectively inhibit both ENT1 and ENT2 isoforms in HL-1 cells (9) . In contrast, the nucleoside analog NBTI is a tight-binding high-affinity inhibitor for ENT1 and will inhibit adenosine uptake via ENT1 at nanomolar concentrations. ENT1 is responsible for the majority of adenosine uptake in HL-1 cells (9) . Therefore, to determine whether inhibition of adenosine uptake by ENT1, ENT2, or both modulates glucose transport, we measured , and NBTI (10-500 nM). We found a dose-dependent decrease in glucose transport with dipyridamole and dilazep but no effect on basal levels of glucose transport with NBTI (Fig. 2) . Glucose uptake was reduced at least 50% with dipyridamole and dilazep at concentrations we have previously determined (9) to fully inhibit adenosine transport (by ENT1 and ENT2). However, inhibition of ENT1 by NBTI has no effect on glucose uptake. These data suggested that inhibition of adenosine reuptake (leading to an increase in extracellular adenosine and activation of receptors) does not modulate glucose transport. Rather, these data suggest that dipyridamole and dilazep inhibit glucose uptake, possibly in a dose-dependent manner.
Dose dependence of glucose uptake inhibition by dipyridamole and dilazep.
To further analyze the inhibition of glucose uptake by dipyridamole and dilazep, we conducted doseresponse assays with a wider range of concentration of inhibitors and calculated the IC 50 values for inhibition of glucose uptake by these compounds (Fig. 3) . The IC 50 for dipyridamole was 12.2 M (pooled data, n ϭ 5, each experiment conducted in quintuplicate) and 5.7 M for dilazep (pooled data, n ϭ 6, each experiment conducted in quintuplicate). Insulin stimulation leads to a recruitment of GLUT4 to the plasma membrane in cardiomyocytes (3). Therefore, we also determined inhibition profiles of dipyridamole and dilazep on glucose uptake in insulin-stimulated HL-1 cells in an attempt to determine whether one isoform was being preferentially inhibited. We found virtually no difference in the IC 50 of dipyridamoleinhibited glucose uptake between basal and insulin-stimulated states (12.22 vs. 13.09 M). There was an increase in the IC 50 of dilazep-inhibited glucose uptake (5.6 vs. 19 M) representing a slightly less effective inhibition of this drug on insulinstimulated cells. In contrast to dipyridamole and dilazep, there was no effect of NBTI (100 nM) on insulin-stimulated glucose uptake in HL-1, which correlates with our observation of no effect on basal glucose uptake (n ϭ 2, data not shown).
Effect of adenosine on basal and insulin-stimulated glucose uptake. Clinical use of dipyridamole and dilazep is based on the premise that these drugs increase extracellular levels of adenosine (by preventing reuptake of adenosine), which, in turn, activates adenosine receptor-dependent pathways promoting cardiovascular well being. Because dipyridamole and dilazep inhibit glucose uptake directly, using them to study adenosine receptor-dependent regulation of glucose uptake is problematic. Extracellular levels of endogenous adenosine are generally relatively low (under normal conditions) and the half-life of adenosine is relatively short because it is rapidly deaminated to inosine (56) . Therefore, to determine whether an increase in extracellular adenosine could modulate glucose transport, we treated cells directly with adenosine [in the presence of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) to prevent degradation] and measured both basal and insulinstimulated glucose uptake. We found no statistically significant difference between basal and insulin-stimulated levels of glucose uptake in the presence or absence of EHNA (data not shown). Glucose uptake in HL-1 cardiomyocytes was stimulated by insulin approximately threefold (Fig. 4A) . However, in both basal and insulin-stimulated cells, we found no statistically significant difference in glucose uptake relative to control in the presence of varying concentrations of adenosine or 2-chloro-adenosine (Fig. 4B) , suggesting that adenosine does not modulate basal or insulin-stimulated glucose uptake in HL-1 cardiomyocytes. 
DISCUSSION
Adenosine is a remarkable molecule that has a diversity of actions both inside and outside of cells. The relationship between adenosine and regulation of glucose transport has been widely investigated and appears to be critically important in skeletal muscle (16, 55) and in insulin-stimulated glucose transport in adipocytes (30, 50) . The evidence supporting a role for adenosine in the regulation of glucose transport in heart is less convincing. Our findings correlate with data from several recent studies in rat cardiomyocytes (11, 20, 22) suggesting that adenosine does not modulate glucose transport in rodent cardiomyocytes. Indeed, it has been suggested that earlier reports (1, 32, 34) of regulation by adenosine of glucose uptake in cardiomyocytes were due to the effects on metabolism rather than transport. Therefore, it would appear that there are significant cell type or tissue-specific differences in the role of adenosine in modulation of glucose transport. Indeed, in cardiomyocytes, nucleotides such as cGMP and ATP, rather than nucleosides, have been shown to modulate glucose transport (7, 22) .
An unexpected result of our study was the observation of a dose-dependent inhibition of glucose transport (both basal and insulin stimulated) by the nucleoside transport inhibitors dipyridamole and dilazep but not NBTI. NBTI is nucleoside analog and differs considerably in structure compared with dipyridamole, a pyrimidopyrimidine and dilazep, an alkyldiamine aromatic ester (see Fig. 5 ). The nature of the molecular interactions between these inhibitors and ENTs is not yet known, although dipyridamole and dilazep are proposed to interact at the same site on the human ENT1 protein, which overlaps with, but may not be identical to, the binding site for NBTI (26) . Moreover, dipyridamole and dilazep inhibit both ENT1 and ENT2 isoforms, whereas NBTI inhibits only ENT1, suggesting that dipyridamole and dilazep possess similar molecular characteristics of interaction with ENTs compared with NBTI. This correlates with our observations of similar effects of dipyridamole and dilazep but distinct (i.e., no) effects of NBTI on glucose uptake.
Dipyridamole and dilazep have been widely used as cardioprotectants because of their properties as nucleoside transport inhibitors, which prevent reuptake of adenosine, thereby enhancing extracellular adenosine levels and potentiating adeno- sine receptor-activated processes, which compensate for cellular stresses, such as hypoxia and ischemia (e.g., 21, 26) . Dipyridamole is also used clinically as an antiplatelet agent in prevention of secondary stroke (e.g., 13, 51). However, dipyridamole has previously been reported to inhibit the organic cation transporter (OCT) (6) , with an IC 50 value (7.7 M) that is very similar to our findings. GLUT1 and GLUT4 are both present at the cardiomyocyte cell membrane under basal conditions, although the proportion of GLUT4 at the plasma membrane increases in response to insulin (3) . On the basis of these observations, a significant shift or change in shape of inhibition profiles under insulin-stimulation could have been indicative of preferential inhibition of one isoform (predominantly GLUT1 under basal conditions) to the other (predominantly GLUT4 under insulin-stimulated conditions). However, our data are inconclusive with regard to whether one isoform is preferentially inhibited compared with the other, but our findings do demonstrate that inhibition occurs in both physiologically relevant conditions.
The inhibition of three different transporter families (GLUT, OCT, and ENT) by dipyridamole (Table 1) suggest that these proteins possess common structural motifs. Indeed, the GLUT and OCT families of proteins are considered members of the sugar porter superfamily of transport proteins (40) and both GLUT1 and OCT1 possess significant sequence similarity at the amino acid level. The relationship of the ENTs to the sugar porter superfamily is not clear but a more detailed analysis of common amino acids and motifs within these different proteins may provide insight into some aspects of tertiary structure of transporters. Indeed, both computational and in vivo approaches, based on transporter substrate (inhibitor) binding studies, are now being used to elucidate transporter structures (4, 59) .
Clinically, the use of dipyridamole to promote cardiovascular health is complicated by the observation that high doses are actually proischemic (23, 42) . It has been proposed that high doses of dipyridamole lead to high concentrations of extracellular adenosine and activation of low-affinity (A 2a ) adenosine receptors. A 2a receptor activation is further proposed to result in cellular and vascular responses, which compromise the cardioprotectant effects of low-dose dipyridamole (which results in activation of high-affinity A 1 adenosine receptors only) (23, 42) . Our data suggest that direct inhibition of glucose uptake may be an additional mechanism responsible for the proischemic effects of high concentrations of dipyridamole. Lower concentrations of dipyridamole are anti-ischemic because only adenosine reuptake is inhibited and adenosine receptor activation is potentiated (see Table  1 ). In humans, the IC 50 value of the ENTs to inhibition of nucleoside uptake with dipyridamole is in the nanomolar range (43) . However, dipyridamole is typically administered orally (e.g., 5, 23), and, whereas plasma levels of adenosine have been found to rise after administration, the concentration of dipyridamole present at the cardiomyocyte membrane is not clear. Moreover, the observation that administration of glucose in combination with dipyridamole treatment reduces ischemic injury in an animal model (8) suggests that monitoring of plasma levels of dipyridamole in patients may be advantageous to ensure that levels do not rise to the point where glucose (or organic cation) uptake is compromised. In addition, our data suggest that extended treatment with dipyridamole or dilazep should be avoided because it may promote development of unexpected side effects. Unanticipated complications have been described for indinavir, a protease inhibitor widely used in anti-human immunodeficiency virus treatment, which has recently been found to also inhibit GLUT4, thereby contributing to the insulin resistance seen in patients using this drug (27, 36) .
In addition to transport inhibition, other cellular effects have been described for both dipyridamole [inhibition of cGMP phosphodiesterase (14) ] and dilazep (antioxidant free radical scavenger) (37, 45) . Thus these observations need to be taken into account in interpretation of data from experiments where dipyridamole and dilazep have been used exclusively as nucleoside transport inhibitors.
In summary, we have found that extracellular adenosine does not modulate glucose uptake in cardiomyocytes. However, the compounds dipyridamole and dilazep, which are used clinically to inhibit adenosine transport and enhance extracellular adenosine, may themselves affect glucose uptake by directly inhibiting transport glucose via the GLUTs under both basal and insulin-stimulated conditions.
